Biotech Values

[DewDiligence]

Five Prime Therapeutics (FPRX) files with SEC for IPO:

http://www.sec.gov/Archives/edgar/data/1175505/000119312513304936/d536956ds1.htm#rom536956_10

We are a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics… We have developed a library of more than 5,600 human extracellular proteins, which we believe represent substantially all of the body’s medically important targets for protein therapeutics. We screen this comprehensive library with our proprietary high-throughput protein screening technologies to identify new targets for protein therapeutics. This platform has allowed us to develop a pipeline of novel product candidates for cancer and inflammatory diseases and to generate over $220 million under our collaboration arrangements.

With a few minor changes, this could’ve been the description of MLNM, INCY, or HGSI circa 2000.